Symptoms Associated With Chemotherapy and Biotherapy-Induced Peripheral Neuropathy

2.50
Hdl Handle:
http://hdl.handle.net/10755/154759
Type:
Presentation
Title:
Symptoms Associated With Chemotherapy and Biotherapy-Induced Peripheral Neuropathy
Abstract:
Symptoms Associated With Chemotherapy and Biotherapy-Induced Peripheral Neuropathy
Conference Sponsor:Sigma Theta Tau International
Conference Year:2003
Conference Date:July 10-12, 2003
Author:Visovsky, Constance
P.I. Institution Name:Case Western Reserve University
Objective: The purpose of this prospective, exploratory pilot study was to determine the pattern of symptoms indicative of peripheral neuropathy resulting from cancer treatment with neurotoxic chemotherapy or biotherapy.<P> Design: A prospective, exploratory design was used. <P> Population, Sample, Setting, Years: A convenience sample of 16 (8 men, 8 women X age 59, range 28-79) subjects with ovarian, lung cancer or malignant melanoma receiving chemotherapy (carboplatin/taxol) or biotherapy (interferon-alpha) were recruited from ambulatory cancer treatment centers from January 2000-January 2001. Variables Studied Together: Independent variables: age, gender and cumulative drug dose. Outcome variables: sensation, gait/ balance, vision, hearing, vibratory sense, deep tendon reflexes, and blood pressure. Methods: Subjects were approached for study participation prior to their first treatment. Peripheral nerve function measures were taken at baseline, 4 and 12 weeks of treatment. Data were analyzed using plots and graphs to determine change over time in peripheral nerve function. Findings: Peripheral neuropathy symptoms effectively doubled over 12 weeks. Declines in hearing (5%), cutaneous sensation (11%), vibratory sensation (9%), deep tendon reflexes (21%), muscle strength (12%), and visual acuity (32%) were experienced. Alterations in orthostatic blood pressure were experienced from baseline to 4 weeks, while gait/balance remained stable. <P> Conclusions: Declines in peripheral nerve measures of hearing, vision, sensation, vibration, deep tendon reflexes and muscle strength occurred with cumulative drug dosage. No change in gait and balance was detected. The most severe orthostatic changes in blood pressure occurred during the first 4 weeks of treatment. Implications: The characterization of peripheral nerve changes can assist in understanding the symptom trajectory of drug-induced neuropathy and aid in preparing patients for lifestyle adjustments and functional limitations. Study findings are essential to foster the development of interventions aimed at preserving functional status and decreasing symptom distress in patients receiving cancer treatment with neurotoxic agents.
Repository Posting Date:
26-Oct-2011
Date of Publication:
10-Jul-2003
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleSymptoms Associated With Chemotherapy and Biotherapy-Induced Peripheral Neuropathyen_GB
dc.identifier.urihttp://hdl.handle.net/10755/154759-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Symptoms Associated With Chemotherapy and Biotherapy-Induced Peripheral Neuropathy</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2003</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">July 10-12, 2003</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Visovsky, Constance</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Case Western Reserve University</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">cxv6@po.cwru.edu</td></tr><tr><td colspan="2" class="item-abstract">Objective: The purpose of this prospective, exploratory pilot study was to determine the pattern of symptoms indicative of peripheral neuropathy resulting from cancer treatment with neurotoxic chemotherapy or biotherapy.&lt;P&gt; Design: A prospective, exploratory design was used. &lt;P&gt; Population, Sample, Setting, Years: A convenience sample of 16 (8 men, 8 women X age 59, range 28-79) subjects with ovarian, lung cancer or malignant melanoma receiving chemotherapy (carboplatin/taxol) or biotherapy (interferon-alpha) were recruited from ambulatory cancer treatment centers from January 2000-January 2001. Variables Studied Together: Independent variables: age, gender and cumulative drug dose. Outcome variables: sensation, gait/ balance, vision, hearing, vibratory sense, deep tendon reflexes, and blood pressure. Methods: Subjects were approached for study participation prior to their first treatment. Peripheral nerve function measures were taken at baseline, 4 and 12 weeks of treatment. Data were analyzed using plots and graphs to determine change over time in peripheral nerve function. Findings: Peripheral neuropathy symptoms effectively doubled over 12 weeks. Declines in hearing (5%), cutaneous sensation (11%), vibratory sensation (9%), deep tendon reflexes (21%), muscle strength (12%), and visual acuity (32%) were experienced. Alterations in orthostatic blood pressure were experienced from baseline to 4 weeks, while gait/balance remained stable. &lt;P&gt; Conclusions: Declines in peripheral nerve measures of hearing, vision, sensation, vibration, deep tendon reflexes and muscle strength occurred with cumulative drug dosage. No change in gait and balance was detected. The most severe orthostatic changes in blood pressure occurred during the first 4 weeks of treatment. Implications: The characterization of peripheral nerve changes can assist in understanding the symptom trajectory of drug-induced neuropathy and aid in preparing patients for lifestyle adjustments and functional limitations. Study findings are essential to foster the development of interventions aimed at preserving functional status and decreasing symptom distress in patients receiving cancer treatment with neurotoxic agents.</td></tr></table>en_GB
dc.date.available2011-10-26T13:15:19Z-
dc.date.issued2003-07-10en_GB
dc.date.accessioned2011-10-26T13:15:19Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.